Patents Represented by Attorney Jeffrey A. Hagenah

Find this attorney in the Justia Lawyer Directory

  • Diaryl ether ?adrenergic receptor agonists
    Patent number: 7662815
    Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: February 16, 2010
    Assignee: Theravance, Inc.
    Inventors: Robert Murray McKinnell, Edmund J. Moran
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 7659403
    Abstract: The invention provides compounds of formula I: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: February 9, 2010
    Assignee: Theravance, Inc.
    Inventors: YongQi Mu, Yu-Hua Ji, Mathai Mammen, Viengkham Malathong
  • Cross-linked glycopeptide-cephalosporin antibiotics
    Patent number: 7655621
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: February 2, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Cross-linked glycopeptide-cephalosporin antibiotics
    Patent number: 7649080
    Abstract: This invention provides cross-linked glycopeptide-cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: January 19, 2010
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 7642355
    Abstract: The invention provides compounds of formula I: wherein a, b, c, p, W, A, X1, R1, R2, R3, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: January 5, 2010
    Assignee: Theravance, Inc.
    Inventors: YongQi Mu, Yu-Hua Ji, Mathai Mammen, Eric L. Stangeland
  • Substituted pyrrolidine and related compounds
    Patent number: 7638639
    Abstract: This invention is directed to compounds of formula I: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: December 29, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Adam Hughes, Yu-hua Ji, Li Li, Weijiang Zhang
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 7632847
    Abstract: The invention provides compounds of formula I: wherein a, b, c, m, n, q, r, W, Z1, Ar1, Z2, Y, R1, R2, and R3 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: December 15, 2009
    Assignee: Theravance, Inc.
    Inventors: YongQi Mu, Yu-Hua Ji, Mathai Mammen, Viengkham Malathong
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 7629336
    Abstract: The invention provides compounds of formula I: wherein a, b, c, d, n, R1, R2, R3, R6, R7, W, and A are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: December 8, 2009
    Assignee: Theravance, Inc.
    Inventors: Yu-Hua Ji, Craig Husfeld, Li Li, Mathai Mammen, YongQi Mu, Eric L. Stangeland
  • 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
    Patent number: 7622508
    Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: February 28, 2007
    Date of Patent: November 24, 2009
    Assignee: Theravance, Inc.
    Inventors: Daniel D. Long, Timothy J. Church, John R. Jacobsen, Lan Jiang, Daisuke Roland Saito, Ioanna Stergiades, Priscilla M. Van Dyke, Sean Dalziel, Leticia Maria Preza
  • Crystalline form of a benzimidazole-carboxamide medicinal compound
    Patent number: 7622587
    Abstract: The invention provides crystalline forms of the novel benzimidazole-carboxamide 5-HT4 receptor agonist compound, 4-(4-{[(2-isopropyl-1H-benzoimidazole-4-carbonyl)amino]methyl}-piperidin-1-ylmethyl)piperidine-1-carboxylic acid methyl ester. The invention also provides pharmaceutical compositions comprising the crystalline compound, methods of using the compound to treat diseases associated with 5-HT4 receptor activity, and processes useful for preparing crystalline forms of the compound.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: November 24, 2009
    Assignee: Theravance, Inc.
    Inventors: Sean M. Dalziel, Kirsten M. Phizackerley
  • Aryl aniline derivatives as ?adrenergic receptor agonists
    Patent number: 7622467
    Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: January 11, 2005
    Date of Patent: November 24, 2009
    Assignee: Theravance, Inc.
    Inventors: Robert M. McKinnell, John R. Jacobsen, Sean G. Trapp, Daisuke R. Saito
  • Substituted pyrrolidine and related compounds
    Patent number: 7615566
    Abstract: This invention is directed to compounds of formula I: wherein R1-R5 and a-e are as defined in the specification; or pharmaceutically-acceptable salt or solvate or stereoisomer thereof. The invention also directed to pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors using such compounds.
    Type: Grant
    Filed: January 30, 2008
    Date of Patent: November 10, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Adam Hughes, Yu-hua Ji, Li Li, Weijiang Zhang
  • Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
    Patent number: 7604944
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: October 20, 2009
    Assignee: Theravance, Inc.
    Inventors: Roger Briesewitz, John H. Griffin
  • Cross-linked glycopeptide-cephalosporin antibiotics
    Patent number: 7601690
    Abstract: This invention provides cross-linked glycopeptides—cephalosporin compounds and pharmaceutically acceptable salts thereof which are useful as antibiotics. This invention also provides pharmaceutical compositions containing such compounds; methods for treating bacterial infections in a mammal using such compounds; and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: October 13, 2009
    Assignee: Theravance, Inc.
    Inventors: Paul R. Fatheree, Martin S. Linsell, Daniel Marquess, S. Derek Turner
  • Quinolinone-carboxamide compounds as 5-HT, receptor agonists
    Patent number: 7592355
    Abstract: The invention provides novel quinolinone-carboxamide 5-HT4 receptor agonist compounds. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: June 29, 2007
    Date of Patent: September 22, 2009
    Assignee: Theravance, Inc.
    Inventors: Daniel Marquess, Paul R. Fatheree, S. Derek Turner, Daniel D. Long
  • Biphenyl compounds useful as muscarinic receptor antagonists
    Patent number: 7585879
    Abstract: This invention provides compounds of formula I: wherein a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7, and R8 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such compounds to treat pulmonary disorders.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: September 8, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Yu-Hua Ji, YongQi Mu, Craig Husfeld, Li Li
  • Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
    Patent number: 7585653
    Abstract: Oncokinase fusion polypeptides associated with hyperproliferative disorders and the polynucleotides encoding for such fusion polypeptides are provided. The fusion polypeptides have a C-terminal tyrosine kinase domain fused to an N-terminal domain that is not normally fused to the C-terminal tyrosine kinase domain and they possess constitutively activated tyrosine kinase activity. Also provided are methods for detecting and identifying the fusion polypeptides and polynucleotides and methods of diagnosing disease conditions associated with the fusion polypeptides and polynucleotides. In addition, screening assays for identifying agents useful for treating disease conditions associated with such fusion polypeptides and polynucleotides are provided. Furthermore, methods of treating disease conditions associated with the presence of the fusion polypeptides are provided.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: September 8, 2009
    Assignee: Theravance, Inc.
    Inventors: Roger Briesewitz, John H. Griffin
  • Aryl aniline ?adrenergic receptor agonists
    Patent number: 7582765
    Abstract: The invention provides novel ?2 adrenergic receptor agonist compounds of formula (I): wherein R1-R13 and w have any of the values described in the specification. The invention also provides combinations of such compounds and other therapeutic agents, pharmaceutical compositions comprising such compounds and combinations, methods of using such compounds to treat diseases associated with ?2 adrenergic receptor activity, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: May 22, 2007
    Date of Patent: September 1, 2009
    Assignee: Theravance, Inc.
    Inventors: Edmund J. Moran, John R. Jacobsen, Michael R. Leadbetter, Matthew B. Nodwell, Sean G. Trapp, James Aggen, Timothy J. Church
  • Process for preparing substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds
    Patent number: 7572918
    Abstract: Processes and intermediates for preparing substituted 4-amino-1-(pyridylmethyl)-piperidine and related compounds in high yield and high purity are described. The substituted 4-amino-1-(pyridylmethyl)piperidine and related compounds prepared by the described processes are useful as muscarinic receptor antagonists.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: August 11, 2009
    Assignee: Theravance, Inc.
    Inventors: Matthew J Peterson, Junning Lee, Richard J Lee, Weijiang Zhang
  • Compounds having ?adrenergic receptor agonist and muscarinic receptor antagonist activity
    Patent number: 7569586
    Abstract: This invention provides compounds of formula I: wherein R1, R2, R3, R4,R5, R6, R7, R8a, R8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both ?2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: August 4, 2009
    Assignee: Theravance, Inc.
    Inventors: Mathai Mammen, Trevor Mischki, Adam Hughes, Yu-Hua Ji